InspireMD, Inc.NSPREarnings & Financial Report
InspireMD Inc. is a global medical device company specializing in innovative interventional cardiology and neurovascular solutions. Its flagship MGuard embolic protection stent line is engineered to reduce complications during vascular procedures, serving clinical customers across North America, Europe, and key Asia-Pacific markets, with a core focus on improving patient outcomes for acute coronary syndrome and stroke care.
NSPR Q4 FY2025 Key Financial Metrics
Revenue
$3.1M
Gross Profit
$1.2M
Operating Profit
$-12.1M
Net Profit
N/A
Gross Margin
37.5%
Operating Margin
-383.7%
Net Margin
N/A
YoY Growth
61.6%
EPS
$-0.11
InspireMD, Inc. Q4 FY2025 Financial Summary
InspireMD, Inc. reported revenue of $3.1M (up 61.6% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $2.0M, operating expenses totaled $13.3M.
Key Financial Metrics
| Total Revenue | $3.1M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 37.5% |
| Operating Margin | -383.7% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
InspireMD, Inc. Q4 FY2025 revenue of $3.1M breaks down across 2 segments, led by Other at $1.7M (55.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $1.7M | 55.0% |
| US | $1.4M | 45.0% |
InspireMD, Inc. Revenue by Segment — Quarterly Trend
InspireMD, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and US) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Other | $1.7M | $1.4M | — | — |
| US | $1.4M | — | — | — |
InspireMD, Inc. Annual Revenue by Year
InspireMD, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.0M).
InspireMD, Inc. Quarterly Revenue & Net Profit History
InspireMD, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.1M | +61.6% | N/A | N/A |
| Q3 FY2025 | $2.5M | +39.4% | $-12.7M | -503.7% |
| Q2 FY2025 | $1.8M | +2.2% | $-13.2M | -739.7% |
| Q1 FY2025 | $1.5M | +1.2% | $-11.2M | -730.3% |
| Q4 FY2024 | $1.9M | +10.7% | N/A | N/A |
| Q3 FY2024 | $1.8M | +16.3% | $-7.9M | -435.9% |
| Q2 FY2024 | $1.7M | +5.5% | $-7.9M | -454.8% |
| Q1 FY2024 | $1.5M | +22.0% | $-7.0M | -465.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | $1.8M | $1.9M | $1.5M | $1.8M | $2.5M | $3.1M |
| YoY Growth | 22.0% | 5.5% | 16.3% | 10.7% | 1.2% | 2.2% | 39.4% | 61.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $42.0M | $55.7M | $50.5M | $46.8M | $38.7M | $33.3M | $78.5M | $69.4M |
| Liabilities | $6.9M | $8.9M | $9.1M | $10.7M | $10.3M | $13.1M | $14.4M | $14.2M |
| Equity | $35.1M | $46.8M | $41.4M | $36.1M | $28.3M | $20.2M | $64.1M | $55.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.1M | $-4.4M | $-5.7M | $-6.8M | $-8.8M | $-8.3M | $-8.6M | $-9.3M |